We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aquestive Therapeutics Inc | NASDAQ:AQST | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.26 | 7.93% | 3.54 | 3.50 | 3.54 | 3.54 | 3.26 | 3.30 | 1,705,602 | 00:45:12 |
Delaware
|
001-38599
|
82-3827296
|
(State or Other Jurisdiction
of Incorporation or Organization)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02
|
Results of Operations and Financial Condition
|
Item 7.01
|
Regulation FD Disclosure.
|
Item 8.01
|
Other Events.
|
Item 9.01
|
Financial Statements and Exhibits
|
Exhibit Number
|
Description
|
|
Press Release, dated November 6, 2018,
announcing financial results for its third
quarter ended September 30, 2018
|
||
Press Release, dated November 2, 2018, announcing the
FDA’s approval
Sympazan®
(clobazam) Oral Film (OF)
|
Dated: November 6, 2018
|
Aquestive Therapeutics, Inc.
|
|
By:
|
/s/ John T. Maxwell
|
|
Name: John T. Maxwell
|
||
Title: Chief Financial Officer
|
1 Year Aquestive Therapeutics Chart |
1 Month Aquestive Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions